Showing 1041-1050 of 1484 results for "".
- Ambulatory Surgery Centers Eligible For New Relief Grant Fundshttps://modernod.com/news/ambulatory-surgery-centers-eligible-for-new-relief-grant-funds-on-april-24/2477642/The Department of Health and Human Services (HHS) announced that, commencing April 24, health care providers, including ASCs, will be eligible to receive grants from a newly available pool of COVID-19 relief funds, according to The Outpatient Ophthalmic Surgery Society (OOSS). These grants are a
- OD-OS Introduces the Navilas expertLibrary Forum for Retina Specialistshttps://modernod.com/news/od-os-introduces-the-navilas-expertlibrary-forum-for-retina-specialists/2480093/OD-OS has introduced a new forum for retina specialists – the Navilas expertLibrary. The Navilas expertLibrary is an exclusive forum where leading retinal physicians share their day-to-day experience with this novel navigated retinal laser technology, according to OD-OS. Interested parties
- Whitney Hauser, OD, FAAO, Joins Novartis Ophthalmicshttps://modernod.com/news/whitney-hauser-od-faao-joins-novartis-ophthalmics/2478318/Novartis has announced that Whitney Hauser, OD, FAAO, will be joining the team as Director, Peer Education for US Ophthalmics. In this capacity, Dr. Hauser will bring her experience as a professor, clinician and founder of the Dry Eye Coach to help shape Novartis’ education and engagement
- Mitotech Granted Orphan Drug Designation by FDA for Visomitin in LHONhttps://modernod.com/news/mitotech-granted-orphan-drug-designation-by-fda-for-visomitin-in-lhon/2480520/Luxembourg-based Mitotech SA announced that the FDA has granted orphan drug designation (ODD) for the company’s topical cardiolipin peroxidation inhibitor, Visomitin, for the treatment of Leber’s Hereditary Optic Neuropathy (LHON), a rare inherited condition that can lead to blin
- FDA Grants Fast Track Designation to Aldeyra’s ADX-2191 for Retinitis Pigmentosahttps://modernod.com/news/fda-grants-fast-track-designation-to-aldeyras-adx-2191-for-retinitis-pigmentosa/2484124/The FDA has granted Fast Track Designation for Aldeyra Therapeutics' ADX-2191 (methotrexate intravitreal injection, USP) for the treatment of retinitis pigmentosa (RP). The FDA’s Fast Track progra
- Eversight Awards 2020-2021 Eye & Vision Research Grantshttps://modernod.com/news/eversight-awards-2020-2021-eye-vision-research-grants/2479233/The Eversight Center for Vision and Eye Banking Research has awarded five grants to investigators at Harvard Medical School, University of Illinois College of Medicine, and Wayne State Universit
- Fred Dubick, OD, Named Optometrist of the Year by California Optometric Associationhttps://modernod.com/news/burbank-eye-doctor-named-optometrist-of-the-year-by-california-optometric-association/2479011/The California Optometric Association (COA) announced that Fred Dubick, OD, MBA, FAAO, has been named the “Optometrist of the Year.” Dr. Dubick is an optometrist and owner of StudioEyes Optometry with locations in Burban
- OD-OS to Celebrate 10 Years of the Navilas Laser Systems at EURETINAhttps://modernod.com/news/od-os-to-celebrate-10-years-of-the-navilas-laser-systems-at-euretina/2479864/OD-OS, the inventor of the Navilas laser systems, is celebrating 10 years of retina navigation with expert sessions at the upcoming EURETINA 2018 conference in Vienna, September 21-25, booth C207. <
- American Academy of Optometry Foundation Announces the 2020-2021 Allergan Foundation Research Grant Recipientshttps://modernod.com/news/american-academy-of-optometry-foundation-announces-the-2020-2021-allergan-foundation-research-grant-recipients/2478375/The American Academy of Optometry Foundation (AAOF), in partnership with the Allergan Foundation, has announced two grant recipients this year in the areas of the anterior segment and glaucoma. The recipient of the Allergan Foundation Grant in the area of the anterior segment is Suzanne MJ
- 4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DMEhttps://modernod.com/news/4dmt-announces-rmat-designation-granted-by-fda-for-4d-150-for-dme/2482776/4D Molecular Therapeutics announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to 4D-150 for the treatment of diabetic macular edema (DME). RMAT designation is part of the 21st Century Cures Act and was created to expedite the developmen